PL1856537T3 - Sposób sprawdzania i kontroli procesu fermentacji kwasu mlekowego u ssaków/ścieżki metabolicznej tlenowej fermentacji glukozy w organizmie ssaczym - Google Patents

Sposób sprawdzania i kontroli procesu fermentacji kwasu mlekowego u ssaków/ścieżki metabolicznej tlenowej fermentacji glukozy w organizmie ssaczym

Info

Publication number
PL1856537T3
PL1856537T3 PL06723195T PL06723195T PL1856537T3 PL 1856537 T3 PL1856537 T3 PL 1856537T3 PL 06723195 T PL06723195 T PL 06723195T PL 06723195 T PL06723195 T PL 06723195T PL 1856537 T3 PL1856537 T3 PL 1856537T3
Authority
PL
Poland
Prior art keywords
mammalian
checking
controlling
metabolic pathway
agf
Prior art date
Application number
PL06723195T
Other languages
English (en)
Inventor
Johannes Coy
Original Assignee
Johannes Coy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05004930A external-priority patent/EP1701165A1/en
Application filed by Johannes Coy filed Critical Johannes Coy
Publication of PL1856537T3 publication Critical patent/PL1856537T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/54Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving glucose or galactose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00Sampling; Preparing specimens for investigation
    • G01N1/28Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/30Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
PL06723195T 2005-03-07 2006-03-03 Sposób sprawdzania i kontroli procesu fermentacji kwasu mlekowego u ssaków/ścieżki metabolicznej tlenowej fermentacji glukozy w organizmie ssaczym PL1856537T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05004930A EP1701165A1 (en) 2005-03-07 2005-03-07 Therapeutic and diagnostic uses of TKTL1 and inhibitors and activators thereof
EP05013170 2005-06-17
PCT/EP2006/001951 WO2006094716A1 (en) 2005-03-07 2006-03-03 Method for ckecking and controlling the mammalian lactic acid fermentation process/aerobic glucose fermentation metabolic pathway in mammalian organism
EP06723195A EP1856537B1 (en) 2005-03-07 2006-03-03 Method for checking and controlling the mammalian lactic acid fermentation process/aerobic glucose fermentation metabolic pathway in mammalian organism

Publications (1)

Publication Number Publication Date
PL1856537T3 true PL1856537T3 (pl) 2011-10-31

Family

ID=36224891

Family Applications (2)

Application Number Title Priority Date Filing Date
PL06723195T PL1856537T3 (pl) 2005-03-07 2006-03-03 Sposób sprawdzania i kontroli procesu fermentacji kwasu mlekowego u ssaków/ścieżki metabolicznej tlenowej fermentacji glukozy w organizmie ssaczym
PL10009323T PL2256500T3 (pl) 2005-03-07 2006-03-03 Zastosowanie inhibitorów enzymu TKTL1

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL10009323T PL2256500T3 (pl) 2005-03-07 2006-03-03 Zastosowanie inhibitorów enzymu TKTL1

Country Status (11)

Country Link
US (3) US7754437B2 (pl)
EP (2) EP1856537B1 (pl)
JP (1) JP5095600B2 (pl)
AT (1) ATE509279T1 (pl)
AU (1) AU2006222277B2 (pl)
CA (1) CA2600206C (pl)
DK (2) DK2256500T3 (pl)
ES (1) ES2480416T3 (pl)
PL (2) PL1856537T3 (pl)
PT (1) PT2256500E (pl)
WO (1) WO2006094716A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007013903A1 (de) 2007-03-20 2008-09-25 Coy, Johannes F., Dr. Getränk
DE102010007243B4 (de) * 2010-02-09 2011-11-17 Frank Kischkel Therapieoptimierung bei Krebspatienten durch Austesten von Therapiekombinationen mittels in vitro Testungen (Zusatz)
DE102011008016A1 (de) 2011-01-06 2012-07-12 Johannes F. Coy Schokoladenmasse
DE102020116980A1 (de) 2020-06-27 2021-12-30 TAVARGENIX GmbH Verwendung von Co-Enzym-Antagonisten zur Stoffwechselverlangsamung
CN112730734A (zh) * 2020-12-22 2021-04-30 河南星汉生物科技有限公司 一种葡萄糖发酵乳酸中发酵液残糖的检验方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4006219A (en) * 1972-08-10 1977-02-01 Ceres Pharmacal Company Composition and method for countering effects of alcohol consumption
DE2834706A1 (de) * 1978-08-08 1980-02-14 Boehringer Mannheim Gmbh Verfahren und reagens zur bestimmung von glutamat-oxalacetat-transaminase und glutamat-pyruvat-transaminase
US4594237A (en) * 1984-04-16 1986-06-10 Walter Ziegler Method for testing chemical and biological substances
EP1290186A2 (en) * 2000-05-31 2003-03-12 Bayer Aktiengesellschaft Regulation of a human transketolase-like enzyme
US7381713B2 (en) * 2000-12-04 2008-06-03 Sioan-Kettering Institute For Cancer Research Treatment of cancer by reduction of intracellular energy and pyrimidines
ES2298304T3 (es) * 2002-04-19 2008-05-16 Johannes Dr. Coy Composiciones y procedimientos para la deteccion y tratamiento de anormalidades proliferativas asociadas con la sobreexpresion de gen like-1 de transcetolasa humano.

Also Published As

Publication number Publication date
US7754437B2 (en) 2010-07-13
PL2256500T3 (pl) 2014-10-31
CA2600206C (en) 2011-01-04
ES2480416T3 (es) 2014-07-28
US20080095703A1 (en) 2008-04-24
EP1856537B1 (en) 2011-05-11
CA2600206A1 (en) 2006-09-14
EP2256500A3 (en) 2012-08-29
DK1856537T3 (da) 2011-07-18
EP1856537A1 (en) 2007-11-21
ATE509279T1 (de) 2011-05-15
US20200248227A1 (en) 2020-08-06
EP2256500B1 (en) 2014-04-23
AU2006222277A1 (en) 2006-09-14
US20100240687A1 (en) 2010-09-23
JP2008531065A (ja) 2008-08-14
EP2256500A2 (en) 2010-12-01
US11236381B2 (en) 2022-02-01
WO2006094716A1 (en) 2006-09-14
AU2006222277B2 (en) 2011-04-07
PT2256500E (pt) 2014-07-18
DK2256500T3 (da) 2014-07-14
JP5095600B2 (ja) 2012-12-12
US11359225B2 (en) 2022-06-14

Similar Documents

Publication Publication Date Title
JP2638593B2 (ja) 被分析物を測定するデバイス及び被分析物の測定法
Armiger et al. The interpretation of on-line process measurements of intracellular NADH in fermentation processes
PL1856537T3 (pl) Sposób sprawdzania i kontroli procesu fermentacji kwasu mlekowego u ssaków/ścieżki metabolicznej tlenowej fermentacji glukozy w organizmie ssaczym
BRPI0418539A (pt) sistema de teste de analito para a determinação da concentração de um analito em um fluido fisiológico
JP5018104B2 (ja) 細胞培養方法及び細胞培養装置
Dietzsch et al. On-line multiple component analysis for efficient quantitative bioprocess development
CL2008003629A1 (es) Metodo de analisis microbiologico de muestras biologicas que comprende un primer intervalo de tiempo de incubacion, tras el cual las muestras que dividen en 3 categorias (positivas, negativas o inciertas) dependiendo de la cantidad de dioxido de carbono generado, y donde las muestra que presentan un contenido de dioxido de carbono comprendido entre un valor maximo y minimo (muestras inciertas), se someten a un segundo intervalo de tiempo de incubacion y asi categorizarlas como positivas o negativas.
Rajan et al. Monitoring pH, temperature and humidity in long-term stem cell culture in CO 2 incubator
EP2662453A3 (en) Detection and treatment of schizophrenia
WO2018052834A1 (en) Self regulating bioreactor apparatus and methods
Horvath et al. In situ fluorescence cell mass measurements of Saccharomyces cerevisiae using cellular tryptophan
CN103528915A (zh) 智能型压感式bod测定仪
EP0036274B1 (en) Methods of monitoring micro-organisms and media for culture
Rolfe Sensing in tissue bioreactors
EP3458816B1 (en) Gas measurement method and device for batch fermentation and in-vitro analysis platforms
Håkanson et al. General sampling system for sterile monitoring of biological processes
Reddy et al. Studies on stress-susceptibility: the relationship between serum enzyme changes and the degree of stress-susceptibility
EP1512003A2 (en) Method and apparatus for measuring nitric oxide production and oxygen consumption in cultures of adherent cells
Kaleybar et al. Performance evaluation of a novel conceptual bioprocess for clinically-required mass production of hematopoietic cells
Roda et al. Microdialysis and luminescent probe: analytical and clinical aspects
Atmanto et al. Culture media
Allman Bioreactors: design, operation, and applications
Berezhetska et al. Conductometric Biosensor Based on Flavocytochrome b 2 for L-Lactate Determination
CN208023017U (zh) 一种血液感染微生物的快速检测系统
US20230008576A1 (en) A host-microbe co-culture perfusion bioreactor for discovery of secreted products and novel interactions at the human-microbiota interface